Evidence map›Paper›PMID 42573696›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Studying Glycan-Dependent ERAD of Misfolded Glycoproteins in Plants.

Ulrike Vavra, Christiane Veit, Richard Strasser

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ulrike VavraDepartment of Biotechnology and Food Science, Institute of Plant Biotechnology and Cell Biology, BOKU University, Vienna, Austria.
Christiane VeitDepartment of Biotechnology and Food Science, Institute of Plant Biotechnology and Cell Biology, BOKU University, Vienna, Austria.
Richard StrasserDepartment of Biotechnology and Food Science, Institute of Plant Biotechnology and Cell Biology, BOKU University, Vienna, Austria. richard.strasser@boku.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The endoplasmic reticulum (ER) is the site where proteins that are synthesized and destined for the secretory pathway fold into their native conformations. Genetic mutations, oxidative stress, reduced glycosylation, and disruption to ER folding and quality control systems are all factors that have been demonstrated to impair this process, leading to the production of misfolded proteins. It is imperative for the survival of cells that these misfolded proteins are recognized by specific signals and directed towards degradation via ER-associated degradation (ERAD), ER-phagy, or related ER-to-lysosome/vacuole transport processes. A pivotal step in this process is the recognition of specific degrons and the distinction between terminally misfolded proteins that necessitate clearance and folding intermediates that have the potential to reach their final conformation. A significant proportion of proteins that traverse the secretory pathway in eukaryotes undergo N-glycosylation. The attached N-glycans not only facilitate the folding and quality control of glycoproteins, but can also be processed to display a glycan degron signal necessary to initiate ERAD of glycoproteins. Here, we describe methods for investigating glycan-related degrons that are key determinants for the ERAD of misfolded glycoproteins in plants.

Indexed as

ArabidopsisEndoplasmic Reticulum-Associated DegradationGlycoproteinsPolysaccharidesDegronsEndoplasmic ReticulumGlycosylationProtein FoldingProteolysisGlycoproteinsPolysaccharidesArabidopsis thalianaERADGlycoproteinN-glycosylationProtein degradationQuality control

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.